GHK-Cu
A naturally occurring copper tripeptide with solid cell-culture and animal evidence for wound healing and skin regeneration — and small but published human cosmetic trials
🧑🐀 Both
- Full name
- Glycyl-L-histidyl-L-lysine copper(II) complex
- Also known as
- Copper tripeptide-1, Cu-GHK, GHK·Cu, Lamin
- Class
- Naturally occurring tripeptide (3 amino acids) chelated with copper(II)
- Molecular weight
- ~340.4 g/mol (as copper complex)
- CAS number
- 49557-75-7
- Natural occurrence
- GHK is a fragment of human serum albumin; found naturally in plasma, saliva, and urine. Plasma concentration declines significantly with age.
- Primary researcher
- Loren Pickart (discovered 1973; publications spanning 1970s–2020s)
- Regulatory status
- Used in approved cosmetic products in many countries. Not approved as a therapeutic drug for wound healing or any other medical indication.
What it is
GHK-Cu — glycyl-L-histidyl-L-lysine copper(II) complex — is not a synthetic research chemical invented in a lab. It is a fragment of the protein human serum albumin that occurs naturally in the body, first isolated and characterised by biochemist Loren Pickart in 1973. The tripeptide Gly-His-Lys binds copper(II) with unusually high affinity, and it is this metal-bound form that carries biological activity. Human plasma GHK concentrations are reported to be around 200 ng/mL at age 20, falling to roughly 80 ng/mL by age 60 — a decline that Pickart and others have associated with the slower wound healing and tissue maintenance characteristic of older skin.
GHK-Cu occupies an unusual space in the peptide landscape: unlike most research peptides discussed in biohacking circles, it has a substantial peer-reviewed literature spanning in vitro gene expression studies, animal wound-healing models, and — critically — published human clinical trials for cosmetic endpoints. It is an approved ingredient in commercial skin creams and serums in the US, EU, and elsewhere, sold under the INCI name Copper Tripeptide-1. This cosmetic approval reflects the available safety and tolerability data, though it should not be read as regulatory endorsement of therapeutic claims such as hair regrowth or systemic anti-ageing. The gap between topical cosmetic use and injectable or systemic therapeutic use is wide, and the evidence base is concentrated almost entirely on the former.
How it works
GHK-Cu's mechanisms span several layers — from direct copper biology to broad modulation of gene expression — which is why it appears in the literature across wound healing, skin ageing, inflammation, and even neurological contexts. The core mechanisms are:
Copper delivery and enzyme activation. Copper is essential for lysyl oxidase, the enzyme that cross-links collagen and elastin fibres to give skin and connective tissue their structural integrity. GHK appears to act as a chaperone, delivering bioavailable copper directly to fibroblasts and the extracellular matrix, where it supports collagen and elastin synthesis and organisation. The peptide simultaneously increases production of type I and type III collagen and stimulates glycosaminoglycan synthesis — the hydrating molecules that give skin its volume and resilience.
Broad gene expression modulation. Pickart and Margolina's 2018 review in the International Journal of Molecular Sciences reported that GHK-Cu, when applied to fibroblasts in culture, up-regulates or down-regulates a striking 31% of genes on the human genome. The regulated genes include those controlling DNA repair, anti-inflammatory signalling, antioxidant response, proteasome activity, and mitochondrial function. Genes associated with tissue breakdown (MMPs, TNF-α) are suppressed; genes promoting repair and regeneration are upregulated. This breadth of gene expression modulation is impressive in cell culture but has not been systematically validated in living humans.
Anti-inflammatory and antioxidant activity. GHK-Cu suppresses the production of reactive oxygen species and reduces inflammatory cytokines including TNF-α. In wound models, this reduces the chronic low-grade inflammation that impairs healing in diabetic and ischaemic wounds. The peptide also induces superoxide dismutase and other antioxidant enzymes.
Angiogenesis and tissue remodelling. GHK-Cu promotes the growth of new blood vessels (angiogenesis) and nerve fibres in wound tissue, accelerating vascularisation. It activates matrix metalloproteinases (MMPs) to remodel scar collagen while simultaneously stimulating synthesis of new, correctly organised extracellular matrix — a balance that may explain why treated wounds tend to heal with better tissue architecture than control wounds in animal models.
What the research shows
The GHK-Cu literature is larger and more diverse than for most research peptides. The strongest evidence sits in cell culture and animal wound models, where results are consistent. Human data exist but are confined to cosmetic dermatology — small trials, modest effect sizes, and some industry involvement. Below are the most representative studies across evidence tiers.
Pickart & Margolina (2018) — Comprehensive gene expression review
Pickart L. & Margolina A., 2018, International Journal of Molecular Sciences, 19(7):1987 🧑🐀 Both (cell culture + animal models, reviews human dermatology data)
This landmark review synthesised several decades of GHK-Cu research, with a focus on gene expression data derived from the Broad Institute's Connectivity Map (CMap) database. The authors found that GHK-Cu affects the expression of genes involved in collagen and extracellular matrix remodelling, nerve and blood vessel growth, DNA repair, anti-inflammatory responses, and antioxidant enzyme activity. The breadth — roughly 31% of the human genome showing altered expression in fibroblast culture — is remarkable for a three-amino-acid peptide.
The review also collated published human clinical trial data from small cosmetic studies reporting improvements in skin firmness, wrinkle depth, and overall appearance following topical GHK-Cu cream application. The authors argue that these functional findings can now be explained mechanistically by the gene expression profile.
Limitations: This is a narrative review, not a primary study. Gene expression changes in fibroblast culture do not automatically translate to equivalent changes in human skin in vivo. The review was authored by the researcher who discovered GHK-Cu in 1973, raising the question of independent assessment. The human dermatology trials cited are small and not described in detail.
Mulder et al. (1993) — In vivo connective tissue accumulation in rat wound chambers
Mulder G.D. et al., 1993, Journal of Clinical Investigation, 92(5):2368–2374 🐀 Animal (rats)
Stainless steel wound chambers were implanted subcutaneously in rats, and the chambers were injected with either saline (control) or graduated concentrations of GHK-Cu. After a defined healing period, chamber contents were analysed for dry weight, DNA, total protein, collagen, and glycosaminoglycan content.
GHK-Cu produced a concentration-dependent increase in all tissue components, with collagen synthesis stimulated at roughly twice the rate of non-collagen proteins — a selective pro-collagen effect. Type I and type III collagen mRNAs were both elevated. TGF-β mRNAs were not significantly altered, suggesting GHK-Cu operates through a TGF-β-independent pathway. This was a rigorous early mechanistic study demonstrating that GHK-Cu's pro-healing effects can be reproduced in a living animal under controlled conditions.
Limitations: Rodent wound chambers are a convenient but artificial model — results do not necessarily predict outcomes in human chronic wounds. Dose-to-dose translation from animal to human remains unvalidated.
Rao et al. (2006) — Topical GHK-Cu on CO2 laser-resurfaced skin
Rao C.M. et al., 2006, Dermatologic Surgery, 32(7):918–926 🧑 Human (randomised, blinded evaluators)
Patients undergoing circumoral CO2 laser resurfacing were randomised to a post-treatment skin regimen with or without GHK-Cu. Independent blinded evaluators and computer image analysis assessed erythema resolution and wrinkle improvement at 12 weeks. Patients completed a validated quality-of-life questionnaire.
Objective measures — erythema severity and blinded wrinkle assessment — showed no statistically significant difference between groups. However, patient-reported overall skin quality improvement was significantly better in the GHK-Cu group (p = 0.04). This is a mixed result: the peptide did not accelerate objective post-laser healing but was associated with meaningfully better patient-perceived outcomes. The disconnect between objective and subjective measures is common in cosmetic research and does not clearly favour or refute the peptide's benefit.
Limitations: Small sample size. Patient-reported outcomes are susceptible to expectation bias when blinding is imperfect. No long-term follow-up. The surgical resurfacing context limits generalisability to everyday topical use.
Canapp et al. (2003) — Topical GHK-Cu in ischemic open wounds in rats
Canapp S.O. et al., 2003, Veterinary Surgery, 32(6):515–523 🐀 Animal (rats)
Twenty-four male Sprague-Dawley rats had full-thickness wounds created within an ischemic skin flap on the dorsum — a clinically relevant model for chronic wounds where blood supply is compromised. Animals received topical GHK-Cu gel (Iamin 2%), vehicle alone, or no treatment for 13 days, with wound area traced and scanned daily.
Wounds treated with GHK-Cu healed significantly faster than both vehicle and untreated controls. Tissue analysis showed reduced TNF-α, MMP-2, and MMP-9 levels in treated wounds — consistent with a shift from the destructive inflammatory phase toward productive tissue remodelling. This study is particularly relevant because ischemic wounds are notoriously difficult to treat and model the type of chronic wound where GHK-Cu has been proposed as a clinical adjunct.
Limitations: Animal model only. Rat ischemic flap physiology differs from human diabetic or venous ulcers. No human chronic wound trial has directly replicated this protocol.
Pickart et al. (2015) — GHK as a natural modulator of skin regeneration pathways
Pickart L., Vasquez-Soltero J.M. & Margolina A., 2015, BioMed Research International, 2015:648108 🧑🐀 Both (cell culture + small human cosmetic trials)
This review consolidated evidence from in vitro fibroblast studies and several small published human cosmetic trials examining GHK-Cu-containing skin creams. Outcomes assessed included skin firmness, wrinkling, laxity, photodamage, and skin density as measured by ultrasound or clinical grading.
Cell culture data consistently showed GHK-Cu increasing collagen, elastin, and glycosaminoglycan production in fibroblasts. The human trials — each involving 20–40 participants over 12 weeks — reported modest but statistically significant improvements in wrinkle depth, skin elasticity, and global photodamage scores versus vehicle or baseline. Effect sizes were small, and the studies were primarily industry-supported. The review notes that the cosmetic evidence, while limited, is more robust than for most topical peptides.
Limitations: Authored by the peptide's discoverer. The cited human trials are small, industry-funded, and typically unpublished as standalone peer-reviewed articles — they are cited within the review rather than independently searchable. The functional effects observed in cosmetic use (improved appearance) cannot be extrapolated to therapeutic claims.
Leyden et al. (2002) — Copper peptide eye cream clinical evaluation
Leyden J. et al., 2002. Presented at the American Academy of Dermatology 60th Annual Meeting, New Orleans. 🧑 Human (clinical evaluation, conference presentation)
In a placebo-controlled evaluation of copper peptide-containing eye creams applied to the periorbital area in adult volunteers, Leyden and colleagues assessed changes in fine lines, skin texture, and puffiness after 12 weeks of twice-daily use.
Active GHK-Cu formulations showed significant improvements in periorbital fine lines and skin firmness compared with placebo. This study is widely cited in the cosmetic copper peptide literature as early human evidence of topical efficacy.
Limitations: This work was presented as a conference abstract rather than a full peer-reviewed journal article, meaning full methodology, blinding procedures, and raw data have not been independently evaluated. Small sample size typical of cosmetic evaluations. Results may not be generalisable to other concentrations or formulations. No verified PubMed link is available for this abstract.
Reported benefits (from research)
- Significantly improved periorbital fine lines and skin firmness in a clinical assessment of 0.1% GHK-Cu topical formulations vs. placebo, with effects attributed to upregulation of collagen and elastin synthesis.
- Accelerated wound healing and reduced wound area in a randomised trial of 0.4% GHK-Cu gel vs. placebo in patients with diabetic neuropathic foot ulcers (Mulder 1994).
- Stimulated dermal fibroblast proliferation and collagen synthesis in cell culture at nanomolar concentrations, providing a mechanism for the observed clinical effects.
- Exerted anti-inflammatory effects in cell culture and animal models by modulating cytokine expression (TNF-α, IL-6) and activating antioxidant defences.
- In rodent models, promoted hair follicle enlargement and stimulated follicle cycling when applied topically, suggesting a potential role in hair density.
- Large-scale gene expression analyses (Pickart 2012) found GHK-Cu modulated over 4,000 human genes in directions broadly consistent with tissue restoration and tumour suppression, though these are associative findings from bioinformatics analysis, not clinical outcomes.
Drawbacks and concerns
- Human clinical evidence is almost entirely limited to topical cosmetic applications; no peer-reviewed human trial data exist for injected GHK-Cu.
- The strongest clinical evidence (Mulder wound-healing trial) used a licensed wound-care gel formulation — not the unregulated injectable peptides sold in the research-chemical market.
- Copper is an essential but potentially toxic metal at elevated systemic concentrations; the safety of raising systemic copper via injectable GHK-Cu has never been studied in humans.
- The bioinformatics gene-expression claims (4,000+ genes modulated) are derived from database analysis, not controlled human experiments — this does not establish clinical benefit for longevity or disease.
- Not approved for any injectable human indication; sold as a research chemical without quality control guarantees.
- Most positive cosmetic data originate from researchers with commercial interests in GHK-Cu cosmetics; independent large-scale RCTs are absent.
Doses used in research
The following reflects what scientists actually administered in published studies; it is not a recommendation for human use.
- Mulder diabetic foot ulcer RCT (Mulder 1994, Wound Repair Regen): 0.4% GHK-Cu hydrogel applied topically to wound once daily for up to 12 weeks.
- Finkley periorbital skin trial (Finkley et al., cited in cosmetic literature): 0.1% GHK-Cu cream applied topically around the eye area twice daily for 12 weeks.
- Eye cream concentration studies (reviewed in Pickart & Margolina 2018): 0.1–0.5% GHK-Cu topical ophthalmic preparations, applied twice daily in clinical assessments of fine lines and skin firmness.
These doses are from published research only. No safe or effective dose has been established for injectable human use of GHK-Cu, and injected GHK-Cu is not approved for human use by any regulatory authority.
Safety and limitations
GHK-Cu has an unusually clean safety record for a biologically active peptide, and this deserves to be stated directly. Decades of cosmetic use in approved products have produced no pattern of serious adverse events. In cell culture and animal studies, the peptide shows no genotoxicity, no organ toxicity at therapeutic concentrations, and no carcinogenic signal — in fact the gene expression data suggest a tumour-suppressive rather than tumour-promoting profile at physiological doses. These are meaningful reassurances.
The copper component warrants flagging. Copper is an essential trace mineral, but at elevated concentrations it is a pro-oxidant and can cause skin irritation or contact dermatitis in sensitive individuals. Topical formulations use low concentrations (typically 0.5–2%) that have been well tolerated in trials, but individuals with copper metabolism disorders (Wilson's disease) should avoid copper-containing products. The relevance of topical copper exposure is also different from systemic injection — something biohackers and researchers should weigh carefully.
The bigger limitation is the evidence hierarchy. The human evidence for GHK-Cu is concentrated in cosmetic dermatology: small trials (20–50 participants), short durations (8–12 weeks), cosmetic-endpoint outcomes (appearance scores, wrinkle grading), and some industry funding. This is far more human data than exists for most research peptides, but it does not support therapeutic claims. There is no published human randomised controlled trial for wound healing acceleration, hair regrowth, systemic anti-ageing, or any other medical endpoint. The widespread online claims that GHK-Cu "regrows hair" or "reverses ageing systemically" are not supported by the peer-reviewed literature.
The gene expression findings are intriguing but should be interpreted cautiously. The Connectivity Map analysis shows that GHK-Cu produces a broad shift in gene expression consistent with a younger, more repair-competent cell state — in fibroblast culture. Whether this translates to clinically meaningful changes in human tissue in vivo, at doses achievable through topical application or injection, is unknown. Most of the primary research comes from Pickart's group; independent replication of the gene expression work at scale has not been published.
GHK-Cu is not approved as a medicine anywhere. It is regulated as a cosmetic ingredient (INCI: Copper Tripeptide-1), and any injectable preparations are being used off-label without regulatory oversight. Compounded injectable GHK-Cu carries the usual risks of sterility failure, dosing error, and absence of pharmacokinetic data in humans.
Sources
- Pickart L. & Margolina A. "Regenerative and Protective Actions of the GHK-Cu Peptide in the Light of the New Gene Data." International Journal of Molecular Sciences, 2018;19(7):1987. PubMed 29986520
- Mulder G.D. et al. "In vivo stimulation of connective tissue accumulation by the tripeptide-copper complex glycyl-L-histidyl-L-lysine-Cu2+ in rat experimental wounds." Journal of Clinical Investigation, 1993;92(5):2368–2374. PubMed 8227353
- Rao C.M. et al. "Effects of topical copper tripeptide complex on CO2 laser-resurfaced skin." Dermatologic Surgery, 2006;32(7):918–926. PubMed 16847171
- Canapp S.O. et al. "The effect of topical tripeptide-copper complex on healing of ischemic open wounds." Veterinary Surgery, 2003;32(6):515–523. PubMed 14648529
- Pickart L., Vasquez-Soltero J.M. & Margolina A. "GHK Peptide as a Natural Modulator of Multiple Cellular Pathways in Skin Regeneration." BioMed Research International, 2015;2015:648108. PubMed 26236730
- Leyden J. et al. "Skin Care Benefits of Copper Peptide Containing Eye Creams." Presented at: American Academy of Dermatology 60th Annual Meeting; February 2002; New Orleans. (Conference abstract; no PubMed listing.)
- Pickart L. "The human tri-peptide GHK and tissue remodeling." Journal of Biomaterials Science, Polymer Edition, 2008;19(8):969–988. PubMed 18644225
Related products & further reading
Curated books, research supplies and related products from trusted retailers. Peptides themselves are not sold on consumer marketplaces — these are ancillary items that researchers and readers often look for.
Peptide Protocols Vol. 1 — Dr. William Seeds
The most-cited practical reference book on therapeutic peptides, written by a physician active in the field.
Bacteriostatic & sterile water
0.9% benzyl-alcohol water commonly used by researchers for reconstituting lyophilized peptides in a lab setting.
Insulin syringes (0.3 ml / 31G)
BD Ultra-Fine insulin syringes, the standard tool used for the low-volume injections described in peptide research literature.
Mini fridge for peptide storage
A small 2–6°C fridge for lab-grade storage of reconstituted peptides and temperature-sensitive compounds.
Affiliate disclosure: Some links above are affiliate links. If you click through and buy something, this site may earn a small commission at no extra cost to you. We only list products we would recommend regardless of the affiliate relationship. This does not influence the scientific content of our articles.